Protara Therapeutics (TARA) Enterprise Value (2014 - 2026)

Protara Therapeutics (TARA) has reported Enterprise Value for 14 consecutive years, with -$135.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Enterprise Value fell 9.19% year-over-year to -$135.8 million; the TTM figure through Mar 2026 stood at -$135.8 million (down 9.19% YoY), while the FY2025 annual figure was -$155.6 million, up 8.65% from the prior year.
• Enterprise Value improved to -$135.8 million in Q1 2026 per TARA's latest filing, from -$155.6 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$55.2 million in Q1 2024 and bottomed at -$170.3 million in Q4 2024.
• Historically, Enterprise Value has averaged -$106.5 million across 5 years, with a median of -$96.3 million in 2022.
• Annual changes were most pronounced in 2023 — Enterprise Value soared 57.67% — and 2024, when it slumped 159.67%.
• Protara Therapeutics' Enterprise Value stood at -$154.9 million in 2022, then jumped by 57.67% to -$65.6 million in 2023, then plunged by 159.67% to -$170.3 million in 2024, then gained by 8.65% to -$155.6 million in 2025, then rose by 12.71% to -$135.8 million in 2026.
• Business Quant data shows TARA's Enterprise Value at -$135.8 million in Q1 2026, -$155.6 million in Q4 2025, and -$132.7 million in Q3 2025.